SBFM
Sunshine Biopharma, Inc.1.3800
-0.0100-0.72%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
6.77MP/E (TTM)
0.26Basic EPS (TTM)
5.31Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Auditor switch completed
Sunshine Biopharma Inc. dismissed Bush & Associates CPA LLC as its independent auditor and hired M&K CPAS, PLLC, effective September 24, 2025, with board and audit committee approval. No disagreements arose with Bush over accounting principles, disclosures, or audit scope in fiscal years 2023 and 2024, nor any reportable events. The switch happened cleanly. This routine change supports ongoing compliance amid Nasdaq listing demands.
10-Q
Q2 FY2025 results
Sunshine Biopharma posted Q2 revenue of $9.4M, up slightly y/y from $9.3M yet flat q/q, while gross profit jumped 45% y/y to $3.4M on a 63.6% margin—better than last year's 74.7% cost bite—thanks to cheaper finished goods sourcing. But operating loss widened to $2.1M y/y, driven by a $1.1M intangible impairment for uncommercializable licenses, plus higher consulting and salaries; net loss hit $1.8M, or $0.39/share on 4.5M shares, versus $0.49M last year on far fewer shares. YTD revenue rose 8.7% to $18.3M with gross profit up 31% to $6.2M, though net loss deepened to $2.95M from $1.78M amid those costs. Cash swelled to $10.3M on $3.9M financing inflows, including a $1.8M April offering and warrant exercises, with no debt but a pending $5.3M claim from a Nora Pharma exec termination. Free cash flow not disclosed in the 10-Q. Government pricing shifts in Canada's generic market pose ongoing risks.
8-K
Q1 revenues surge 18%
Sunshine Biopharma reported first-quarter 2025 revenues of $8.9 million, up 18% from $7.5 million last year, driven by strong generic drug sales. The company launched six new generics—two antibiotics, two for gastrointestinal disorders, and two for schizophrenia—while appointing Michel Roy as Chief Commercial Officer to bolster commercial efforts. Studies confirmed K1.1 mRNA's potential against liver cancer. Yet net loss narrowed to $1.2 million from $1.3 million. Forward-looking plans include 13 more launches, like NIOPEG® biosimilar, amid SEC-noted risks.
IPO
Employees
Sector
Industry
AMRX
Amneal Pharmaceuticals, Inc.
12.17-0.29
BIOE
Bio Essence Corp.
0.05+0.00
CBDL
CBD Life Sciences Inc.
0.00+0.00
CPHI
China Pharma Holdings, Inc.
1.44-0.09
CRLBF
Cresco Labs Inc.
1.75+0.45
FLGC
Flora Growth Corp.
8.84+0.39
HYPMY
Hypera SA
4.10+0.05
PHBI
Pharmagreen Biotech Inc.
0.00+0.00
PLSH
Panacea Life Sciences Holdings,
0.09+0.00
UPC
Universe Pharmaceuticals Inc
3.68+0.05